A semisynthetic anthracycline antitumor antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Valrubicin

Item No. 22964

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester
CAS Number
56124-62-0
Synonyms
  • NSC 246131
  • N-Trifluoroacetyladriamycin-14-valerate
Molecular Formula
C34H36F3NO13
Formula Weight
723.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlEthanol: 5 mg/ml
λmax
201, 235, 252, 496 nm
SMILES
OC1=C(C[C@](C(COC(CCCC)=O)=O)(O)C[C@@H]2O[C@@](O[C@@H](C)[C@H]3O)([H])C[C@@H]3NC(C(F)(F)F)=O)C2=C(O)C(C4=O)=C1C(C5=CC=CC(OC)=C45)=O
InChi Code
InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
InChi Key
ZOCKGBMQLCSHFP-KQRAQHLDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $94

    Add

    1 mg

    $174

    Add

    5 mg

    $728

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Valrubicin is a semisynthetic anthracycline antitumor antibiotic and derivative of doxorubicin (Item No. 15007).1 It inhibits the growth of human bladder tumor cell lines with LD50 values ranging from 0.05 to 11.2 μM.2 Valrubicin is more active against cells in the plateau growth phase than in the log growth phase (LD70s = 2.5 and 12.1 μM, respectively for CUB-2 cells). Valrubicin (40 mg/kg) increases survival in mice with murine P388 and L1210 leukemias.1 Topical administration of valrubicin (0.01 g/ml) reduces epidermal thickness and normalizes epidermal morphology in a mouse psoriasis xenograft transplantation model.3 Formulations containing valrubicin have been used in the treatment of bladder cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Israel, M., Modest, E.G., and Frei, E., III N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 35(5), 1365-1368 (1975).

    2. Niell, H.B., Hunter, R.F., Herrod, H.G., et al. Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother. Pharmacol. 19(1), 47-52 (1987).

    3. Rosada, C., Stenderup, K., de Darkó, E., et al. Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. J. Invest. Dermatol. 130(2), 455-463 (2010).